Hypermarcas S/A

Consumer Pharmaceuticalshyperapharma.com.br

Hypermarcas S/A (Hypera Pharma) is a B3-listed Brazilian pharmaceutical company that manufactures and sells OTC, prescription, generic, institutional, and skincare products through 35+ brands including Buscopan, Neosaldina, and Neo Química across retail pharmacy, e-commerce, and B2B channels nationwide in Brazil.

Company typePublic
Founded2001
HeadquartersSão Paulo, Brazil
Headcount5,001–10,000
GTM typeB2C
OfferingHardware or Manufacturing

What Hypermarcas S/A does

Hypermarcas S/A, operating commercially as Hypera Pharma, is a Brazilian publicly traded pharmaceutical company listed on B3 under ticker HYPE3 and headquartered in São Paulo. The company manufactures and distributes one of Brazil's largest and most diversified pharmaceutical portfolios, comprising approximately 35+ brands across five core segments: over-the-counter medications (where it holds the leadership position in the Brazilian OTC market with iconic brands such as Buscopan, Neosaldina, Doril, Apracur, and Benegrip); prescription drugs under Mantecorp Farmasa; generic and similar medications under Neo Química (with 65+ years of market history); institutional products for clinics and hospitals; and dermatological skincare via Mantecorp Skincare (40+ years), Simple Organic, and Bioage, plus food and nutritional products. The underlying business is pharmaceutical manufacturing and product development, with no disclosed proprietary technology platforms beyond standard pharma formulation and manufacturing operations.

Hypera Pharma operates a multi-channel distribution model: direct-to-consumer e-commerce through its own storefronts (ihypera.com.br, neoquimica.com.br, mantecorpskincare.com.br), retail pharmacy distribution through chains and independent pharmacies across Brazil, and a dedicated institutional/B2B sales force serving clinics and hospitals. Marketing is conducted through organic social (Instagram, LinkedIn, TikTok), content/news channels, celebrity and influencer partnerships, and joint promotional campaigns with retail pharmacy partners such as Drogaleste. The company also operates Hympar, a digital platform serving healthcare professionals, and pursues ESG positioning through dedicated sustainability, social responsibility, and people initiatives. Revenue is generated through one-time product sales across the diversified portfolio; pricing is not publicly disclosed and varies by segment and channel. The corporate structure consists of wholly-owned subsidiary brands acquired and retained over time, with no parent company.

Hypermarcas S/A firmographics

Firmographics

Name: Hypermarcas S/A
Legal name: Hypermarcas S/A
Website: https://hyperapharma.com.br
Company type: Public
Founded year: 2001
Operating status: Operating
Headcount range: 5,001–10,000 employees
Short description: Hypermarcas S/A (Hypera Pharma) is a B3-listed Brazilian pharmaceutical company that manufactures and sells OTC, prescription, generic, institutional, and skincare products through 35+ brands including Buscopan, Neosaldina, and Neo Química across retail pharmacy, e-commerce, and B2B channels nationwide in Brazil.
Ownership category
akta.pro rank

Hypermarcas S/A industry classification

Industry

Product category: Consumer Pharmaceuticals
NAICS: Biological Product (except Diagnostic) Manufacturing (325414), All Other Specialty Food Retailers (445298)
SIC: Food And Kindred Products (2000), Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro primary industry: Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)
akta.pro secondary industries: Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Generic Hospital & Institutional Products (HLAIABAL), Probiotics & Digestive Health Supplements (CRADAGAF), Specialty & Functional Packaged Foods (Gluten-Free, Keto, Organic, Medical/Allergen-Friendly) (CRADAAAI), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

Pharmaceutical products
OTC medications
Generic medications
Prescription drugs
Dermatological skincare

Where Hypermarcas S/A is headquartered

Location

Headquarters

HQ city: São Paulo
HQ country: Brazil
HQ region: Latin America

Offices1 record

Markets served

Hypermarcas S/A business model

Business model

GTM type: B2C
Offering type: Hardware or Manufacturing
Cost components: Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

Pharmaceutical Product Sales: Hypera Pharma generates revenue through the manufacture and sale of pharmaceutical products across multiple segments including OTC (over-the-counter) medications, prescription drugs, generic and similar medications, institutional market products, and skincare/dermatological products. The company operates one of the largest and most diversified portfolios in the Brazilian pharmaceutical market.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Hypermarcas S/A product offering

Product offering

Core offering

Hypermarcas S/A (operating as Hypera Pharma) manufactures and distributes a diversified portfolio of pharmaceutical products in Brazil across five core segments: over-the-counter (OTC) medications, prescription drugs, generic and similar medications, institutional market products for clinics and hospitals, and skincare/dermatological products. The company also sells food and nutritional products, and operates direct-to-consumer e-commerce and the Hympar digital platform for healthcare professionals. Its brand portfolio includes Buscopan, Neosaldina, Doril, Apracur, Benegrip, Engov, Estomazil, Epocler, Magnazia, Gelol, and Nebacetin.

Product overview

Hypermarcas S/A (operating as Hypera Pharma) is one of the largest pharmaceutical companies in Brazil with a highly diversified portfolio. The company operates across multiple product segments: OTC medications (Isentos de prescrição) where it holds market leadership with iconic brands like Neosaldina, Buscopan, Doril, Apracur, and Merthiolate; prescription medications through Mantecorp Farmasa; generics and similars via Neo Química brand with 65 years of history; institutional market products for clinics and hospitals; skincare with Mantecorp Skincare (40+ years), Simple Organic, and Bioage; and food/nutritional products. The company also owns Hympar, a digital platform for healthcare professionals. Hypera Pharma's portfolio includes approximately 35+ distinct pharmaceutical brands across various therapeutic categories.

Differentiator

Problem solved

Functional benefit

Brands

Neo Química: Generic and similar medications brand with over 65 years of history in the Brazilian pharmaceutical sector
Mantecorp Farmasa
Mantecorp Skincare
Simple Organic
Bioage

Products and services

Over-the-counter (OTC) medications

Companies that use Hypermarcas S/A

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Hypermarcas S/A technology and API

Technology

Technology focussed No

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Hypermarcas S/A partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

DrogalestecoreGTM or Marketing Partner · 5 September 2025Drogaleste pharmacy chain partnered with Neo Química brand for the 'Bando de Prêmios' promotional campaign targeting fans and customers. This is a joint marketing and promotional partnership to drive consumer engagement and sales through loyalty programs.
Juntos Pelo AraguaiaminorOthersSocial responsibility initiative partnership indicated by the 'Selo Juntos Pelo Araguaia' (Seal Together for Araguaia) displayed on the website, representing corporate social responsibility and community support programs.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Hypermarcas S/A competitors and assessment

Company assessment

Broad incumbents

Sanofi Brasil: Brazilian operations of global pharma giant Sanofi, a major player in OTC consumer health (e.g., analgesics, allergy, vitamins) and prescription categories. Sanofi competes with Hypera in OTC and consumer health directly and is a relevant broad incumbent comparison for the consumer health portfolio.
Reckitt Benckiser Brasil: Brazilian operations of global consumer health company Reckitt (Nurofen, Strepsils, Gaviscon). Reckitt is a relevant broad incumbent peer for Hypera's OTC franchise and provides an international comparator focused on branded consumer health categories.
Bayer Brasil: Brazilian arm of global life sciences company Bayer, with a strong consumer health division (analgesics, vitamins, dermatology). Bayer competes with Hypera across multiple OTC and skincare categories and offers a parallel global-to-local diversification reference point.
Johnson & Johnson (Consumer Health) Brasil: Brazilian consumer health operations of Johnson & Johnson, active in OTC, baby care, and skin health categories. J&J competes with Hypera across multiple consumer health categories and is a relevant broad multinational incumbent peer.
GSK Consumer Healthcare (now Haleon) Brazil: Brazilian operations of what is now Haleon, the global consumer healthcare spinoff of GSK. Haleon's OTC portfolio (analgesics, oral health, respiratory) competes directly with Hypera's OTC brands and provides an international benchmark for pure-play consumer health strategic focus.

Direct peers

Cristália Produtos Químicos Farmacêuticos: Brazilian pharmaceutical manufacturer focused on the institutional and hospital market with a growing generics and specialty portfolio. Cristália is a relevant direct comparator for Hypera's institutional/B2B segment and broader Brazilian pharma presence.
EMS: Brazil's largest pharmaceutical company by revenue, EMS is Hypera Pharma's most direct competitor across prescription, generics, OTC, and branded consumer health. Both companies target overlapping therapeutic categories and compete for pharmacy shelf space and institutional contracts throughout Brazil.
Eurofarma Laboratórios: Major Brazilian pharmaceutical manufacturer operating across prescription, generics, OTC, and hospital segments. Eurofarma competes directly with Hypera in branded and generic categories and pursues similar multi-channel distribution strategies including pharmacy and institutional channels.
Biolab Farmaceutica: Brazilian pharma company with strong prescription and specialty pharmaceutical presence, increasingly expanding into OTC and consumer health categories. Biolab competes with Hypera in prescription segments and is a relevant comparator for the Brazilian branded pharma business model.
Aché Laboratórios: One of Brazil's largest pharmaceutical companies with a diversified portfolio spanning prescription, OTC, generics, and consumer health. Aché competes directly with Hypera across multiple therapeutic categories and shares similar national distribution infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Hypermarcas S/A financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hypermarcas S/A leadership team

Management profile

Number of profiles

Hypermarcas S/A subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Hypermarcas S/A funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hypermarcas S/A M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hypermarcas S/A

What does Hypermarcas S/A do?

Is Hypermarcas S/A a public or private company?

Hypermarcas S/A is a public company. It is classified as public and is currently operating.

When was Hypermarcas S/A founded?

Hypermarcas S/A was founded in 2001. It employs 5,001 to 10,000 people.

Where is Hypermarcas S/A based?

Hypermarcas S/A is headquartered in São Paulo, Brazil, in the Latin America region.

How does Hypermarcas S/A make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Hypermarcas S/A's main competitors?

Broad incumbents on record are Sanofi Brasil, Reckitt Benckiser Brasil, Bayer Brasil, Johnson & Johnson (Consumer Health) Brasil and GSK Consumer Healthcare (now Haleon) Brazil. Direct peers are Cristália Produtos Químicos Farmacêuticos, EMS, Eurofarma Laboratórios, Biolab Farmaceutica and Aché Laboratórios.

Does Hypermarcas S/A have an API?

No public API is recorded for Hypermarcas S/A.

What industry is Hypermarcas S/A in?

Hypermarcas S/A's product category is Consumer Pharmaceuticals. Its primary akta.pro industry code is CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges), with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 325414 and its SIC code is 2000.